EGFR and non-small cell lung carcinoma: In studies that followed patients from initial NSCLC diagnosis, the proportion of patients who received second-line treatment ranged from 8% in a population-based Canadian study that did not include oral therapies (epidermal growth factor receptor [EGFR] tyrosine kinase inhibitors [TKIs]) to 53% in a German study at a single institution [20, 24, 25].